Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Natural History Study of Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene

NCT05349019 is registered in ClinicalTrials.gov with Escape Bio, Inc. as lead sponsor.

NCT NCT05349019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05349019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Natural History Study of Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene
Lead sponsor
Escape Bio, Inc.
Phase
Observational
Overall status
Terminated
Start date
May 2, 2022
Completion date
August 5, 2022
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with parkinson's disease (pd) caused by the p.gly2019ser (g2019s) pathogenic mutation of the leucine-rich repeat kinase 2 (lrrk2) gene